Awaiting development: Guidance and quality standards

Showing 31 to 40 of 87

Guidance and quality standards awaiting development
Title	Type
Heart valve disease in adults	Quality standard
Inclisiran for treating familial hypercholesterolaemia and elevated low density lipoprotein cholesterol in people 12 to 17 years [TSID12129]	Technology appraisal guidance
Irbesartan–propagermanium for treating focal segmental glomerulosclerosis in people 12 years and over having an angiotensin II receptor blocker [ID6469]	Technology appraisal guidance
Isatuximab in combination as induction therapy for untreated multiple myeloma when an autologous stem cell transplant is suitable [TSID11949]	Technology appraisal guidance
Isatuximab in combination for maintenance treatment of newly diagnosed multiple myeloma after an autologous stem cell transplant [ID6639]	Technology appraisal guidance
Istradefylline with levodopa for treating motor fluctuations in Parkinson's disease [ID3868]	Technology appraisal guidance
Ixekizumab for treating enthesitis-related arthritis and juvenile psoriatic arthritis in people 2 to 17 years [ID6590]	Technology appraisal guidance
KardiaMobile 6L for measuring cardiac QT interval in adults having antipsychotic medication	HealthTech guidance
Letetresgene autoleucel for treating NY-ESO-1 advanced unresectable synovial sarcoma in people aged 10 and over or NY-ESO-1 advanced unresectable myxoid round cell liposarcoma in adults [TSID10652]	Technology appraisal guidance
Linerixibat for treating pruritus in people with primary biliary cholangitis [ID6265]	Technology appraisal guidance